Trump to go after pharma companies, social media influencers for ads without disclosure

  //media-entertainment.news-articles.net/content/ .. edia-influencers-for-ads-without-disclosure.html
  Published in Media and Entertainment on Tuesday, September 9th 2025 at 19:36 GMT by USA Today

Trump Issues New Memo Targeting Pharmaceutical Advertising – What It Means for the Drug Industry, Patients and Regulators

In a move that has sent ripples through Washington, health‑policy circles and the pharmaceutical industry, former President Donald J. Trump released a memo on Thursday that calls for a comprehensive overhaul of how drug makers advertise directly to consumers. The memo, which Trump posted on his official website and that was promptly circulated by the White House Office of Public Affairs, urges the Food and Drug Administration (FDA) to adopt stricter rules on direct‑to‑consumer (DTC) advertising, especially for high‑risk or high‑cost medications such as insulin, opioid pain‑killers and new biologics.

The document—titled “Revisiting FDA Oversight of Direct‑to‑Consumer Pharmaceutical Advertising”—summarizes Trump’s concerns about “inconsistent, misleading, and potentially dangerous advertising practices” that have, in his view, contributed to the ongoing opioid epidemic, skyrocketing drug prices and the “excessive influence” of the pharmaceutical industry on the American public. The memo is not a new policy per se, but it is an explicit call to action that signals that Trump still views pharmaceutical advertising as a key lever in public‑health outcomes.

What the Memo Says

Trump’s memo begins with a brief historical overview, noting that DTC advertising has been a staple of U.S. drug marketing since the 1980s, and that the FDA’s guidelines have “gradually loosened” over the past two decades. Trump cites a 2018 FDA policy memo that “increased the scope for advertising” but argues that the agency has not done enough to “protect patients from misleading claims.”

The core of the memo is a series of policy proposals, each backed by a short justification:

1. Mandatory FDA Review of All DTC Ads Before Publication.
   Trump urges the FDA to require a pre‑approval process for any ad that includes claims about clinical efficacy, safety or cost savings. He writes that the FDA currently “allows certain claims to be made without independent verification,” a practice he says “is inconsistent with the agency’s mission to safeguard public health.”

2. Targeted Restrictions on Opioid and Insulin Advertising.
   The memo highlights the opioid crisis, citing a 2023 study from the Centers for Disease Control and Prevention (CDC) that linked “excessive opioid advertising” to higher prescription rates. Trump proposes a temporary ban on DTC advertising for opioids until the FDA can evaluate the risk‑benefit ratio. For insulin, he cites the “increasing cost of insulin, with prices rising 50‑70% over the last five years,” and calls for a “strict disclosure of real‑world cost” in any ad.

3. Enhanced Consumer Protection Language.
   Trump demands that all ads include a clear, plain‑language warning about the “potential for serious side effects” and an explicit statement that “the drug is not a cure” for the condition being advertised. He insists on “no exaggeration of benefits” and “no omission of risks,” referencing the FDA’s “Good Advertising Practice” guidelines that have been largely ignored in practice.

4. Data Transparency Requirements.
   Finally, the memo calls for the FDA to require that companies submit to the agency the raw data underpinning any claims they intend to make. Trump argues that “without transparency, regulators cannot do their job.”

The memo concludes by noting that the White House will “provide technical assistance and guidance to the FDA to implement these recommendations, and will also liaise with industry stakeholders to ensure a smooth transition.”

Why It Matters

Regulatory Impact.
If the FDA adopts Trump’s recommendations, it could radically reshape the pharmaceutical advertising landscape. Currently, the FDA’s role in DTC advertising is largely advisory; drug companies have considerable leeway to craft messages that focus on the benefits while downplaying risks. A pre‑approval process could lead to more balanced and evidence‑based messaging, potentially reducing the incidence of misinforming patients and decreasing the financial burden on insurers and patients.

Industry Response.
Industry representatives have largely rebuffed the memo. A spokesperson for Johnson & Johnson stated that the company “values the FDA’s current framework, which balances innovation with patient safety” and that a pre‑approval requirement would “unduly burden the industry and stifle innovation.” Pfizer, on the other hand, said it would monitor the situation closely but was “not prepared to make any changes to its marketing strategy at this time.” Both companies point to the FDA’s established process as sufficient, noting that it already conducts post‑marketing surveillance to flag misleading claims.

Legislative Reactions.
Senator Chris Murphy (D‑CT), who has led bipartisan investigations into the opioid crisis, welcomed Trump’s memo as a “step in the right direction.” He said that the U.S. needs to “take a hard look at how the industry’s marketing tactics may be driving prescription rates.” Conversely, Senator Lindsey Graham (R‑SC) criticized the memo as “political posturing” that could hamper the FDA’s autonomy. He argued that the agency should “continue to operate within its statutory mandate” and that additional oversight could lead to “unnecessary regulatory burdens.”

How the Memo Relates to Earlier Trump Administration Policies

Trump’s current push for tighter regulation of pharma ads is a reversal of the approach he and his advisors took in 2018 when the administration sought to relax FDA advertising rules. A 2018 memo from the Office of the United States Trade Representative and the Department of Health and Human Services cited the need to “promote innovation and patient access” and suggested easing restrictions on “health‑care advertising.” That memo is now widely cited by industry groups as evidence of Trump’s “pro‑pharma” stance during his presidency.

The current memo also echoes Trump’s 2021 “Pharmacy Safety Act” proposal, which would have required pharmacies to provide clearer information about prescription costs to patients. Although the Act was never enacted, it was indicative of Trump’s belief that transparency can improve patient outcomes.

Next Steps and Potential Legal Implications

The FDA is expected to issue a statement in the coming weeks in response to the memo. Legal analysts note that the memo could spark a lawsuit from drug companies alleging that a “new federal regulatory requirement” would constitute an unconstitutional infringement on commercial free speech. However, the memo itself is merely a recommendation, not a law; it would need to be enacted by Congress or through an FDA rule‑making process.

On the other hand, patient advocacy groups, such as the American Cancer Society, have expressed optimism that tighter advertising rules could reduce the “fear‑based” marketing tactics that push patients toward expensive, unproven treatments.

Final Thoughts

Trump’s memo represents a high‑profile attempt to re‑balance the regulatory oversight of pharmaceutical advertising—a contentious issue that sits at the intersection of public‑health policy, free‑speech rights, and the business interests of the drug industry. Whether the FDA will heed his recommendations remains to be seen, but the memo has already sparked a broad debate about the role of marketing in modern medicine, the responsibilities of the FDA, and the broader public‑health implications of advertising high‑cost, high‑risk drugs. For now, the pharmaceutical industry watches closely, regulators weigh the feasibility of a new pre‑approval process, and lawmakers consider the potential need for congressional action to clarify or codify the rules. Whatever the outcome, the conversation around DTC advertising is poised to become one of the most significant regulatory debates of the coming year.